SECURITIES AND EXCHANGE
COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) of the
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): ~~August~~October 271, 2024 (~~August~~September 1823, 2024)

NIKA PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)

colorado	000-56234	90-0292940
(State or other jurisdiction of Nika Pharmaceuticals, Inc.)	(Commission File Number)	(IRS Employer Identification No.)

2269 Merrimack Valley ~~AvenueHenderson~~Avenue Henderson, NV 89044(Address of principal executive offices) (Zip code)

(702)-326-3615
Registrant's telephone number, including area code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Section 24 –- Matters Related to Accountants and Financial ~~Information~~Statements

Item 24.01 ~~Completion~~Changes ofin ~~Acquisition~~Registrant’s ofCertifying ~~Assets~~Accountant.

On ~~August~~September 1823, 2024, ~~based~~Nika ~~on recommendation of Clifford Redekop~~Pharmaceuticals, ~~officer and director, the board of directors found it in the Nika Pharmaceuticals~~ Inc.’s ~~best~~engaged ~~interest to cancel~~ the ~~acquisition~~firm of ~~Nika Pharmaceuticals,~~OLAYINKA ~~Ltd.,~~OYEBOLA ~~UIC:~~& ~~175420503~~CO ~~that~~(Chartered ~~was~~Accountants) ~~made effective on May 9, 2024 and disclosed via Form 8-K on May 10, 2024. The procedure~~ to ~~return~~serve ~~the~~as 100% to Dimitar Slavchev Savov, who is an officer and director of Nika Pharmaceluticals, Inc. and general manager of Nika Pharmaceuticals, Ltd., was initiated on August 19, 2024 and was made effective on August 23, 2024, resulting in Nika Pharmaceuticals, Ltd. no longer being a wholly owned subsidiary of Nika Pharmaceuticals, Inc. As a result, Nika Pharmaceuticals, Inc. no longer practically owns 99.99% in Nika Europe, Ltd. and is no longer the ~~beneficial owner~~independent ofaccountant ~~the~~to ~~factory~~audit ~~building and land disclosed in~~ the ~~aforementioned~~company’s ~~Form~~financial ~~8-K dated May 10, 2024~~statements.

~~Section 4 - Matters Related to Accountants and Financial~~ ~~Statements~~SIGNATURES ~~Item 4.01 Changes in Registrant’s Certifying Accountant.~~

~~On August 21, 2024 Nika Pharmaceuticals, Inc.’s independent~~ ~~accountant~~Pursuant ~~Fruci~~to ~~& Associates II, PLLC tendered its resignation. The members of~~ the ~~board~~requirements of ~~directors have discussed~~ the ~~issue~~Securities ~~with~~Exchange ~~the~~Act ~~former~~of ~~independent accountant~~1934, ~~and~~the ~~Nika~~Registrant ~~Pharmaceuticals, Inc.~~ has ~~authorized~~duly ~~the~~caused ~~former~~this ~~independent accountant~~Report to ~~respond~~be ~~fully~~signed toon ~~the~~its ~~inquiries~~behalf ofby the ~~successor~~undersigned, ~~accountant concerning~~hereunto ~~historical~~duly ~~data~~authorized.

As the situation was unexpected, Nika Pharmaceuticals, Inc. is still looking for a new firm to serve as the independent accountant to audit the company’s financial statements and will strive to publish its 10-Q as early as possible.

	NIKA PHARMACEUTICALS, INC.

Dated: October 1, 2024	By:	/s/ Dimitar Slavchev Savov
		Dimitar Slavchev Savov
		Chief Executive Officer,
		Director

Item 9.01 Exhibits

(d) Exhibits

23.1 Consent Letter by Fruci & Associates II, PLLC

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.

	NIKA PHARMACEUTICALS, INC.
Dated: August 27, 2024	By:	/s/ Dimitar SlavchevSavov
		Dimitar SlavchevSavov
		Chief Executive Officer,
		Director

Filing Compare · NIKA PHARMACEUTICALS, INC